The Conversation (0)
GT Biopharma announced today the closing of their merger with Georgetown Translational Pharmaceuticals.
GT Biopharma (OTCQB:OXISD) announced today the closing of their merger with Georgetown Translational Pharmaceuticals.
As quoted in the press release:
The merger brings GT Biopharma, Inc a new Chief Executive Officer, a robust intellectual property portfolio, and a multi-million dollar financing that leaves the Company well-positioned to continue pursuing its pipeline of oncology and Central Nervous System (CNS) drugs.
As part of the transaction, GTP shareholders were issued 16,927,878 of GT Biopharma (OTCQB: OXISD) common stock. Also, as a requirement of Closing, GT Biopharma completed a financing of over $4.5 million and retired 100% of the company’s debt. The new funding provides capital for GT Biopharma to continue to pursue regulatory approval of the drugs in its oncology pipeline and newly acquired CNS pipeline. Completion of the merger and elimination of all debt is a key milestone accomplishment which positions GT Biopharma to pursue its strategy for acceptance to the Nasdaq Exchange.
Click here to read the full press release.
Source: www.accesswire.com
